Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Synthesis and Structure-Activity Relationship of Dehydrodieugenol B Neolignans against Trypanosoma cruzi

Full text
Author(s):
Sear, Claire E. [1] ; Pieper, Pauline [1] ; Amaral, Maiara [2, 3] ; Romanelli, Maiara M. [3] ; Costa-Silva, Thais A. [3] ; Haugland, Marius M. [1] ; Tate, Joseph A. [4] ; Lago, Joao H. G. [5] ; Tempone, Andre G. [3] ; Anderson, Edward A. [1]
Total Authors: 10
Affiliation:
[1] Chem Res Lab, Oxford OX1 3TA - England
[2] Univ Sao Paulo, Fac Med, BR-05403000 Sao Paulo - Brazil
[3] Adolfo Lutz Inst, Ctr Parasitol & Mycol, BR-01246000 Sao Paulo - Brazil
[4] Syngenta Ltd, Jealotts Hill Int Res Ctr, Bracknell RG42 6EY, Berks - England
[5] Fed Univ ABC UFBC, Ctr Nat Sci & Humanities, BR-09210580 Santo Andre, SP - Brazil
Total Affiliations: 5
Document type: Journal article
Source: ACS INFECTIOUS DISEASES; v. 6, n. 11, p. 2872-2878, NOV 13 2020.
Web of Science Citations: 0
Abstract

Trypanosoma cruzi is the etiologic agent of Chagas disease, which affects over seven million people, especially in developing countries. Undesirable side effects are frequently associated with current therapies, which are typically ineffective in the treatment of all stages of the disease. Here, we report the first synthesis of the neolignan dehydrodieugenol B, a natural product recently shown to exhibit activity against T. cruzi. Using this strategy, a series of synthetic analogues were prepared to explore structure-activity relationships. The in vitro antiparasitic activities of these analogues revealed a wide tolerance of modifications and substituent deletions, with maintained or improved bioactivities against the amastigote forms of the parasite (50% inhibitory concentration (IC50) of 4-63 mu M) and no mammalian toxicity (50% cytotoxic concentration (CC50) of >200 mu M). Five of these analogues meet the Drugs for Neglected Disease Initiative (DNDi) ``hit criteria{''} for Chagas disease. This work has enabled the identification of key structural features of the natural product and sites where scaffold modification is tolerated. (AU)

FAPESP's process: 18/25128-3 - Optimization of natural scaffolds as new therapeutic candidates for Visceral Leishmaniasis
Grantee:Maiara Amaral de Oliveira
Support Opportunities: Scholarships in Brazil - Doctorate
FAPESP's process: 18/10279-6 - Selection and Optimization of New Drug Candidates for Leishmaniasis and Chagas Disease
Grantee:André Gustavo Tempone Cardoso
Support Opportunities: Regular Research Grants